Cutting-Edge Cancer Treatment Technologies
Lukas Biomedical's memory T cell culture technology has received exclusive authorization from Japan's National Cancer Center. It has completed Phase III clinical trials with Japan's Ministry of Health, Labour and Welfare, and successfully conducted Phase IV clinical trials in South Korea. The technology has obtained drug approval and is now marketed in South Korea, with over 10,000 clinical treatment cases recorded in Japan and South Korea. It has been proven to be a stable and effective method of immunotherapy for cancer treatment.
READ MORE
